The Substance Abuse and Mental Health Services Administration (SAMHSA) reports that combined substance use is common in overdose cases
Modest Human Weight Loss (Phase 2 Data) Evidence quality: Moderate (one phase 2b trial, 300 patients) In a 12-week, randomized, double-blind, placebo-controlled trial with 300 obese adults across five sites, oral AOD-9604 produced measurable but modest weight loss
The product page notes that the serums pH is 6.00-7.00, or ranging from very mildly acidic to neutral
What Should I Expect From Treatment at AgeRejuvenation
BPC-157 Therapy in Houston at a Glance EXPECTED RESULTS Accelerated tissue repair, reduced joint inflammation, and faster recovery from intense workouts
Scientific and Official Sources PubChem: BPC-157 identity, synonyms, molecular formula and mass Sikiric and colleagues: early published BPC-157 research ClinicalTrials.gov: PCO-02 BPC-157 safety and pharmacokinetics study Lee and colleagues: two-participant BPC-157 intravenous pilot study McGuire and colleagues: narrative review of BPC-157 evidence and risk World Anti-Doping Agency: 2026 Prohibited List MHRA: Borderline products and how to tell if a product is a medicine Human Medicines Regulations 2012: Regulation 279 United States FDA: safety risks associated with certain bulk substances, including BPC-157 United States FDA: BPC-157-related bulk-substance briefing document CAP Code Section 12: Medicines and health-related products Health and Safety Executive: UK REACH Health and Safety Executive: Safety Data Sheets and COSHH Health and Safety Executive: COSHH risk assessment Cox and colleagues: identification and analytical detection of BPC-157 in confiscated material
